Gastroenterology

There are many reasons why biosimilars are not utilized in gastroenterology, mainly patients present younger and treatments can lose efficacy over time.

Some traditional sarcopenia assessment techniques included direct measurements on cross sectional imaging, but cross sectional imaging also comes with increased time, cost, and radiation exposure.

The rate of CDI recurrence through week 9 using the efficacy analysis 3 definition was 13.8% for the high-dose VE303 group, compared to 37% for the low-dose VE303 group and 45.5% for the placebo group.

Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.

The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.

April is Donate Life Month, where many advocate for more living organ donors.

Of the patients in the first cohort, 0.7% had HBV, all of which had a history of drug use. In addition, 3% were anti-HCV positive, 8 of which had a history of drug.

Metabolic dysfunction was associated with increased risk of HCC, while patients with only metabolic dysfunction had the highest risk because the sustained virological response achievement.

The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.

Nonoperative management was associated with a 3.72% decrease in the risk of complications and a 1.82% increase in mortality in patients who were aged 65 years and older.

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

Patients with no prior colonoscopy had significantly higher all-cause mortality and colorectal cancer specific mortality compared to patients with detected colorectal cancer.

Increased age, male sex, COPD, CHF, dependent functional status, and C. difficile infection were associated with increased mortality within 30 days of surgery.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

The majority of patients felt it was important for healthcare providers talk to them about the symptoms, possible treatments. In addition, most patients are not prescribed a medication right away.

Among 1660 cases with only PCR data, the cycle threshold was significantly associated with recurrence-free survival.

A nearly two-fold increase or decrease in liver stiffness would be required to confidently represent a change in the underlying fibrosis.

At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.

Patients at a risk of malnutrition had a significantly lower mean of albumin, as well as significantly increased proportion of patients with CRP >5 mg/L.

There is a June 22 PDUFA date for obeticholic acid, which if approved would become the first FDA-approved treatment for NASH.

The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system. The treatment is being evaluated in patients with eosinophilic esophagitis and allergen sensitivity.

The 2 groups had similar data for any endoscopic recurrence and severe endoscopic recurrence at the first endoscopic evaluation.

Acute severe ulcerative colitis and a greater number of biologics precoloectomy were linked to an increased probability of acute pouchitis, while older age at colectomy was associated with a decreased probability of acute pouchitis.

The results from the INSPIRE trial show risankizumab met all primary and secondary endpoints in treating adult patients with moderately to severely active ulcerative colitis.

No single biomarker or multimarker score significantly reached the predefined acceptability thresholds for patients with NASH and clinically significant fibrosis.